|
|
|
Vancouver-based Sierra Oncology Announces Momelotinib Granted FDA 'Fast Track' Designation
|
|
Vancouver, BC, June 11, 2019--Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on advancing targeted therapeutics for the treatment of patients with significant unmet needs in hematology and oncology, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to momelotinib, a JAK1, JAK2 and ACVR1 inhibitor, for the treatment of patients with intermediate/high-risk myelofibrosis who have previously received a JAK inhibitor.
|
|
|
|
|
|
|
|
|
|
Sierra Oncology Reports Robust Transfusion Independence Rates in Transfusion Dependent Myelofibrosis Patients
|
|
Vancouver, BC, January 30, 2019--Sierra Oncology, Inc. (Nasdaq: SRRA), a clinical stage drug development company focused on advancing targeted therapeutics for the treatment of patients with significant unmet needs in hematology and oncology, reported clinical data for its lead drug candidate, momelotinib, a potent, selective and orally-bioavailable JAK1, JAK2 and ACVR1 inhibitor for the treatment of myelofibrosis.
|
|
|
|
|
|
|
|
Sierra Oncology Reports Third Quarter Results - Cash and Cash Equivalents Totaled $107.8 Million
|
|
Vancouver, BC, December 6, 2017--Sierra Oncology, Inc. (NASDAQ: SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer, reported its financial and operational results for the third quarter ended September 30, 2017. Cash and cash equivalents totaled $107.8 million at the end of this quarter.
|
|
|
|
|
|
|
|
|
|
|
|
Sierra Oncology Establishes Distinguished DNA Damage Response Advisory Committee
|
|
Vancouver, BC, September 1, 2017--Sierra Oncology, Inc. (NASDAQ: SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer, announced it has established a DDR Advisory Committee composed of leading experts in this emerging field of cancer drug development.
|
|
|
|
|
|
|
|
|
|
Sierra Oncology Receives Clearance to Enhance Ongoing Clinical Trials for SRA737
|
|
Vancouver, BC, June 20, 2017--Sierra Oncology, Inc. (NASDAQ: SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer, reported that it has received clearance from regulators in the UK to amend the two ongoing Phase 1 trials for its Chk1 inhibitor, SRA737.
|
|
|
|
|
|
|
|
Sierra Oncology Granted US and EU Patents for Chk1 inhibitor SRA737
|
|
Vancouver, BC, June 15, 2017--Sierra Oncology, Inc. (NASDAQ: SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer, reported it has been issued a selection patent for its Chk1 inhibitor, SRA737, from the U.S. Patent and Trademark Office.
|
|
|
|
|
News
Events
Tech Careers
Directory
Tech Stocks
T-Net 100
Members
Feedback
About T-Net
Employers
Post Job Listings
Advertise
